Lilliam Ribeiro

Lilliam Ribeiro has a diverse and extensive work experience in the pharmaceutical industry. Lilliam began their career as a Clinical Research Coordinator at Albert Einstein MC in 2002, followed by a role as Site Manager at Penn Medicine, University of Pennsylvania Health System from 2003 to 2005. Lilliam then joined AstraZeneca as a Clinical Research Scientist, where they managed a global phase IIb Cardiovascular/Renal clinical trial and ensured regulatory compliance with GCP and FDA regulations. In 2007, Lilliam moved to Pfizer, where they worked as a Clinician and later as a Clinical Research Scientist until 2012. Currently, they hold the position of Director for Clinical Safety and Pharmacovigilance at Adaptimmune US, where they are responsible for overseeing clinical safety and pharmacovigilance activities. Overall, Lilliam Ribeiro has demonstrated expertise in various clinical research and safety roles throughout their career.

Lilliam Ribeiro pursued their education in a chronological manner, beginning with their Bachelor's degree in Biology at La Salle University. Lilliam attended from 1998 to 2002, completing their undergraduate studies.

Afterwards, Lilliam Ribeiro furthered their educational journey by pursuing a Master's degree at the University of Pennsylvania School of Medicine. Lilliam enrolled in the years 2004 and graduated in 2006. Lilliam'sfield of study for their Master's degree was Bioethics.

These are the known details of Lilliam Ribeiro's education history, and no further assumptions can be made beyond the provided information.